-0.03 | -6.47%
| Price and Volume | |
|---|---|
| Recent Price | 0.43 |
| 52 Week High | 0.65 |
| 52 Week Low | 0.27 |
| Avg. Daily Vol. (Mil) | 1.51 |
| Beta (3 year) | 2.48 |
| Share Related Items | |
| Mkt Cap (Mil) | 111.15 |
| Shares Out (Mil) | 256.70 |
| Float (Mil) | 249.66 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.70 |
| Current Ratio | 4.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 307.82 |
| Price/Book | 17.81 |
| Price/Cash Flow | -6.50 |
| Per Share Data | |
| Earnings | -0.11 |
| Sales | 0.00 |
| Book Value | 0.02 |
| Cash Flow | -0.07 |
| Business Summary | |
|---|---|
| The Company is engaged in the research and development of drugs and vaccines for the treatment of cancer. | |
| General Information | |
| 8229 Boone Boulevard
Suite 802 Vienna, VA 22182 |
|
| www.cel-sci.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 44 | |
| CEO: Geert R. Kersten | |
| Short Interest | |
| Current Month (Mil) | 10.88 |
| Previous Month (Mil) | 10.43 |
| Short Interest Ratio (Days) | 11.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -95.20 |
| Return on Investments | -280.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,533.58 | 1,324.59 | 2,855.40 | 17.14 |
Oil *
106.38
|
|
UP
78.75 |
UP
6.77 |
UP
17.87 |
DOWN
0.31 |
10 Yr
1.71%
SPDR Gold
150.50
|
|
+0.63%
|
+0.51%
|
+0.63%
|
-1.78%
|
Data delayed 20 minutes |
Connect with TheStreet